ABSTRACT
La biologie moleculaire est aujourd'hui un atout majeur pour la prise en charge adequate de cancer. Le profil genomique tumoral ou sequencage genomique des tumeurs est un test qui permet de dresser l'inventaire des genes d'une tumeur dont l'analyse conduit a identifier les cibles therapeutiques. Leur association avec les donnees cliniques; permet d'etablir un traitement personnalise. Ce procede constitue un recours precieux devant une tumeur multi-resistante aux traitements conventionnels. C'est cette derniere situation que les auteurs ont decidee de presenter; devant un cancer du sein triple negatif; resistant a plusieurs de lignes de chimiotherapie conventionnelle. L'evolution a change apres la realisation du profil genomique et l'ajustement du traitement
Subject(s)
Genomics , Molecular Biology , Triple Negative Breast Neoplasms/therapyABSTRACT
Mycobacterium tuberculosis (MTB) is a formidable microbial pathogen which uses multiple mechanisms to subvert host immune defences. These include the effective; protective barrier presented by the outer waxy coat; intracellular concealment from host defences; and the ability to enter a prolonged; dormant phase in the infected host. Priority strategies to combat the scourge of TB include the identification of novel and selective targets on/in MTB which are amenable to pharmacological or immune-mediated control. Because they are structurally different from their counterparts in eukaryotic cells and are likely to be essential for survival and growth; the major K+ transporters of MTB represent alternative and novel targets for drug and vaccine design. These K+-uptake systems of MTB are the primary focus of this review; with particular emphasis on their genomic and protein structures; properties and functions; and potential roles in intracellular survival